222
Views
13
CrossRef citations to date
0
Altmetric
Case Report

Aripiprazole (Abilify™) Overdose in a Child

, F.A.C.E.P. , M.D. , F.A.C.M.T., , M.D. & , F.A.C.M.T. , M.D.
Pages 193-195 | Published online: 11 Aug 2009

References

  • Tamminga, C A, Carlsson, A. Partial dopamine agonists and dopaminergic stabilizers in the treatment of schizophrenia. Curr Drug Target CNS Neurol Disord 2002; 1(2):141–147. [CSA]
  • Ozdemir, V, Fourie, J, Ozdener, F. Aripiprazole Otsuka Pharmaceutical Co. Curr Opin Invest Drugs 2002; 3(1):113–120. [CSA]
  • Marder, S R, McQuade, R D, Stock, E, Kaplita, S, Marcus, R, Safferman, A Z, Saha, A, Ali, M, Iwamoto, T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003; 61(2–3):123–136. [CROSSREF], [CSA]
  • Shapiro, D A, Renock, S, Arrington, E, Chiodo, L A, Liu, L X, Sibley, D R, Roth, B R, Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28:1400–1411. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
  • Sajatovic, M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiat Rep 2003; 5:320–326. [CSA]
  • Stahl, S M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part II: illustrating their mechanism of action. Clin Neurosci Update 2001; 62(12):923–924. [CSA]
  • Petrie, J L, Saha, A R, McEvoy, J P. Aripiprazole, a new atypical antipsychotic: phase II clinical trial results. Eur Neuropsychopharmacol 2002; 5(suppl 1):S186.
  • Duggal, H S. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiat 2003; 48(11):771–772. [CSA]
  • Grunder, G, Carlsson, A, Wong, D. Mechanism of new antipsychotic medication. Arch Gen Psychiatry 2003; 60:974–977. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
  • Lofton, A L, Kein-Schwartz, W. Atypical experience: a case series of pediatric aripiprazole exposures. J Toxicol Clin Toxicol 2004; 42(5):715–716.
  • Sugiyama, A, Satoh, Y, Hashimoto, K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 2001; 173:120–128. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.